Drug Type Drug conjugates |
Synonyms DK 710, DK710 |
Target |
Action modulators |
Mechanism EGFR modulators(Epidermal growth factor receptor erbB1 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Bladder Cancer | Preclinical | United States | 01 Jul 2024 | |
| Colorectal Cancer | Preclinical | United States | 01 Jul 2024 | |
| Head and Neck Neoplasms | Preclinical | United States | 01 Jul 2024 | |
| Kidney Neoplasms | Preclinical | United States | 01 Jul 2024 | |
| Lung Cancer | Preclinical | United States | 01 Jul 2024 | |
| Pancreatic Cancer | Preclinical | United States | 01 Jul 2024 | |
| Skin Neoplasms | Preclinical | United States | 01 Jul 2024 |





